Which Drugs Require Intensive Monitoring for Toxicity?

March 22nd, 2013 - Seth Canterbury, CPC, ACS-E/M
Categories:   Drugs|Pharmaceuticals|FDA  

Question:

When coding E/M services, what drugs qualify as those requiring “intensive monitoring for toxicity” on the MDM Risk table?

Answer:

Therapeutic drug monitoring is required for a variety of reasons, one of which is a drug’s high potential for toxicity.

Intensive monitoring for toxicity is normally associated with drugs having what’s called a “narrow therapeutic range” or “narrow therapeutic index” (NTI). This means that there is a very small range between the minimum concentration of the drug needed to produce the desired therapeutic effect and the maximum concentration beyond which toxicity or death can result. The concentrations of these drugs must be intensively monitored to ensure that they are in this “sweet spot.”

There is no official US Food and Drug Administration (FDA) or government agency list of narrow therapeutic index (NTI) drugs. However, the Board of Pharmacy of some states maintain a list of what they consider to be NTI drugs, a list used to enforce policies which restrict pharmacists from substituting generic equivalents for these drugs without specific consent from the practitioner and/or patient.

Also, some payers publish lists of drugs they deem to be NTI drugs, such as Wellmark BC/BS as seen at this link: www.wellmark.com/Products/pharmacy/nti.aspx
 

As stated on Wellmark’s site:

Some drugs are identified as having a narrow therapeutic index (NTI) by the Food & Drug Administration (FDA). With NTI drugs, small changes in the dosage could cause toxic results.

Patients taking NTI drugs require constant monitoring so that the level of medication can be adjusted to assure uniform and safe results. Members will not be required to pay the difference in cost between brand and generic for drugs that are classified as NTI medications.

NTI drugs are identified in the Wellmark Drug List.

For coders, I recommend using an NTI drug list from a state pharmacy board or specific payer if possible, as a starting point for determining which drugs fall into the “drugs that require intensive monitoring for toxicity” category, and add any other drugs that physicians inform you also need this intensive monitoring along with the reason these physicians feel this drug qualifies for this status.

###

Questions, comments?

If you have questions or comments about this article please contact us.  Comments that provide additional related information may be added here by our Editors.


Latest articles:  (any category)

Artificial Intelligence in Healthcare - A Medical Coder's Perspective
December 26th, 2023 - Aimee Wilcox
We constantly hear how AI is creeping into every aspect of healthcare but what does that mean for medical coders and how can we better understand the language used in the codeset? Will AI take my place or will I learn with it and become an integral part of the process that uses AI to enhance my abilities? 
Specialization: Your Advantage as a Medical Coding Contractor
December 22nd, 2023 - Find-A-Code
Medical coding contractors offer a valuable service to healthcare providers who would rather outsource coding and billing rather than handling things in-house. Some contractors are better than others, but there is one thing they all have in common: the need to present some sort of value proposition in order to land new clients. As a contractor, your value proposition is the advantage you offer. And that advantage is specialization.
ICD-10-CM Coding of Chronic Obstructive Pulmonary Disease (COPD)
December 19th, 2023 - Aimee Wilcox
Chronic respiratory disease is on the top 10 chronic disease list published by the National Institutes of Health (NIH). Although it is a chronic condition, it may be stable for some time and then suddenly become exacerbated and even impacted by another acute respiratory illness, such as bronchitis, RSV, or COVID-19. Understanding the nuances associated with the condition and how to properly assign ICD-10-CM codes is beneficial.
Changes to COVID-19 Vaccines Strike Again
December 12th, 2023 - Aimee Wilcox
According to the FDA, CDC, and other alphabet soup entities, the old COVID-19 vaccines are no longer able to treat the variants experienced today so new vaccines have been given the emergency use authorization to take the place of the old vaccines. No sooner was the updated 2024 CPT codebook published when 50 of the codes in it were deleted, some of which were being newly added for 2024.
Updated ICD-10-CM Codes for Appendicitis
November 14th, 2023 - Aimee Wilcox
With approximately 250,000 cases of acute appendicitis diagnosed annually in the United States, coding updates were made to ensure high-specificity coding could be achieved when reporting these diagnoses. While appendicitis almost equally affects both men and women, the type of appendicitis varies, as dose the risk of infection, sepsis, and perforation.
COVID Vaccine Coding Changes as of November 1, 2023
October 26th, 2023 - Wyn Staheli
COVID vaccine changes due to the end of the PHE as of November 1, 2023 are addressed in this article.
Medicare Guidance Changes for E/M Services
October 11th, 2023 - Wyn Staheli
2023 brought quite a few changes to Evaluation and management (E/M) services. The significant revisions as noted in the CPT codebook were welcome changes to bring other E/M services more in line with the changes that took place with Office or Other Outpatient Services a few years ago. As part of CMS’ Medicare Learning Network, the “Evaluation and Management Services Guide” publication was finally updated as of August 2023 to include the changes that took place in 2023. If you take a look at the new publication (see references below),....



Home About Terms Privacy

innoviHealth® - 62 E 300 North, Spanish Fork, UT 84660 - Phone 801-770-4203 (9-5 Mountain)

Copyright © 2000-2024 innoviHealth Systems®, Inc. - CPT® copyright American Medical Association